Sobi partners with Innate Pharma to license lacutamab for T-cell lymphoma in USD 75 million deal

Reuters2026/08/10 06:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Swedish Orphan Biovitrum entered a strategic partnership with Innate Pharma to license lacutamab for T-cell lymphoma.
Innate will run the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma to support a planned accelerated approval filing in Sézary syndrome.
Sobi will get exclusive global commercialization rights upon potential accelerated approval; it can take full global development rights after positive Phase 3 results.
Sobi will pay USD 75 million at closing; Innate can earn up to USD 40 million in near-term development milestones.
Innate can receive up to USD 465 million tied to development, regulatory, commercial milestones; it will also earn tiered double-digit royalties on net sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Swedish Orphan Biovitrum AB published the original content used to generate this news brief via Cision (Ref. ID: 20260809:BIT:5705:0) on August 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Sobi partners with Innate Pharma to license lacutamab for T-cell lymphoma in USD 75 million deal

You may also like

Crypto prices